Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect
Don't underestimate this healthcare giant.
Johnson & Johnson, a titan of the global healthcare industry, is often perceived as a steady, growth-resistant investment due to its diversified business model and high credit rating. However, analysts anticipate a shift in the company's trajectory by 2030, with its sales and earnings growth potentially outpacing market expectations.
This projection is rooted in the fact that while Johnson & Johnson's healthcare portfolio has traditionally boasted a robust consumer health segment, this business segment has historically exhibited slower growth compared to the company's biopharma and medtech divisions. Despite this, the company's diverse revenue streams and strong financial standing suggest that by 2030, Johnson & Johnson could become a faster-growing entity than many investors anticipate.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
